|
CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF
CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF
Researchers at Stanford have developed compounds that act as potent anti-cancer drugs which selectively inhibit CDK19 over CD8 and promise a greater therapeutic index and reduced systemic toxicity.
Breast cancer remains the leading cause of cancer-related death among women worldwide. Patient mortality...
Published: 7/6/2023
|
Inventor(s): Vincent Alford, Mark Smith, Michael Clarke, Jitendra Gurjar, Angera Kuo
Keywords(s): CDK19, CDK8, Compound, Selective Inhibition, Therapeutic, Treatment, Triple Negative Breast Cancer
Category(s): Technology Classifications > Biology
|
|
CDK19- SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF
CDK19- SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF
Researchers at Stanford University have identified new CDK19-selective inhibitors for the treatment of triple negative breast cancer.
Breast cancer remains the leading cause of cancer-related mortality among women worldwide. While early cancer detection methods such as genetic biomarker screening...
Published: 3/17/2023
|
Inventor(s): Robert Hsieh, Mark Smith, Michael Clarke, Vincent Alford, Andrew Amant
Keywords(s): CDK19, CDK8, Cyclin Dependent Kinases, Kinase Inhibitor, Triple Negative Breast Cancer
Category(s): Technology Classifications > Chemistry
|
|
METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER
METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER
Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed a method for treating and predicting treatment efficacy of triple negative breast cancer (TNBC).
TNBC is an aggressive subtype of breast cancer that is characterized by a lack of expression of three receptors commonly...
Published: 3/17/2023
|
Inventor(s): Michael Clarke, Robert Hsieh
Keywords(s): Breast Cancer, Cancer, CDK19, Oncology, TNBC, Triple Negative Breast Cancer
Category(s): Technology Classifications > Biology
|
